Clinical Trials Logo

Clinical Trial Summary

The U.S. Environmental Protection Agency has traditionally examined the effects of single pollutant exposure on human health outcomes; however, to provide a better assessment of pollutant exposure-associated effect on human health the Agency is moving toward a multi-pollutant approach. Ozone (O3) and nitrogen dioxide (NO2) are national ambient air quality standards (NAAQS) criteria pollutants that are major constituents of ambient air pollution. This study will address the Agency's goals by investigating the cardiopulmonary health effects of sequential exposure to O3 and NO2 in healthy adult human volunteers. The findings of this study will provide data that will inform risk assessment models for O3 and NO2 exposures. Additionally, the findings will provide insight into how the human health effects of multi-pollutant exposures differ from those of single pollutant exposures.


Clinical Trial Description

Despite improvements in air quality over the past several decades, over 100 million people in the U.S. still live in counties that do not meet the National Ambient Air Quality Standards (NAAQS) for one or more pollutants. During the course of daily living individuals are exposed to multiple pollutants from various sources of both natural and anthropogenic origin. It has become increasingly clear that air pollutant exposure is a risk factor for exacerbation and perhaps even progression of pulmonary and cardiovascular disease. The majority of controlled human exposure studies have examined individual pollutants; however, real-world exposures occur in the context of a complex mixture of pollutants. Different pollutants reach peak levels at different times during the day, which raises the concern that exposure to one pollutant may sensitize an individual so that their response to a subsequent exposure may be enhanced. Thus the sequence of exposure to these agents may affect their relative health effects and result in certain exposure scenarios being more deleterious than others.

To define multi-pollutant exposures that are relevant to real world scenarios we consulted experts in the EPA Office of Air and Radiation (OAR), who advised us to study the effects of sequential exposure to NO2 and O3, two ubiquitous NAAQS criteria pollutants. Ambient diurnal profiles of these two pollutants indicate that levels of NO2 often peak in the evening and morning hours, which are followed by peak ambient O3 concentrations during mid-day. Using this information we designed the study described here to determine whether sequential exposure to NO2 and O3, or O3 and NO2, will result in greater pulmonary and cardiovascular effects than exposure to either pollutant alone. Ozone is a major component of photochemical smog and is one of the most thoroughly studied gaseous pollutants. Controlled human exposure studies have been critical in demonstrating that it can cause airway inflammation, including increases in neutrophil infiltration into the lung and the production of pro-inflammatory mediators, and ultimately decrements in lung function. More recent studies have shown that ozone can also increase vascular inflammation, as well as alter autonomic nervous system control of heart rate. Nitrogen dioxide is an oxidant that is produced by natural and anthropogenic processes. The majority of man-made NO2 results from large-scale combustion-related processes, such as automobile emissions and the generation of electricity. Although traffic-related exposures account for the majority of NO2 emissions. Emissions from natural gas cooking appliances and kerosene-fueled space heaters with inadequate ventilation can serve as a significant source of human exposure to NO2 indoors. Previous studies have shown that NO2 concentrations can reach 600ppb in the area surrounding an operating gas stove, and peak levels may exceed 2000ppb. Controlled human exposure studies have indicated that exposure to NO2 alone (ranging from 110-2000ppb) results in little to no observable decrement in lung function; however, NO2 exposure has been associated with increases in airway hyper-responsiveness, susceptibility to pulmonary infection, and increased pulmonary inflammation. More recently, exposure to 500ppb NO2 has been associated with changes in cardiac electrophysiology. Recent epidemiological data indicate that exposure to NO2 from vehicle emissions were associated with both respiratory and cardiovascular-related mortality. Previous studies have shown that sequential exposure to NO2 and O3 (at concentrations similar to those proposed in this study) results in greater lung function decrements and increased non-specific airway responsiveness compared to O3 exposure preceded by clean air exposure in young women. Additional studies have demonstrated that sequential exposure to ozone, separated by 24 hours, resulted in greater lung function decrements, assessed as forced expiratory volume in the first second of exhalation (FEV1), following the second exposure than was observed after the first. Ozone exposure has also been shown to have a priming effect for subsequent exposure to sulfur dioxide (SO2) in adolescent asthmatics and allergen-induced responses of perennially allergic asthmatics. Additionally, ongoing research at the EPA Human Studies Facility has demonstrated that sequential exposure of humans to diesel exhaust and ozone can result in greater lung function decrement than exposure to either pollutant alone. Given the complex nature of pollutant exposure, we are interested in determining if exposure to one pollutant can sensitize a person so that subsequent exposure to a second pollutant would cause a more pronounced response than would be expected based on exposure to just the second pollutant alone. Thus, in this study we will examine two exposure scenarios involving sequential exposures of NO2 and O3. The first involves determining whether an initial exposure to NO2 will "prime" an individual to a subsequent O3 exposure. The second involves determining whether an initial exposure to O3, at a concentration that results in small cardiopulmonary changes that resolve within 24 hours, will augment a subsequent exposure to NO2. Generally speaking, exposure to NO2 alone is not associated with robust changes in metrics of cardiopulmonary function; however, we believe that it can modify, and be modified by, ozone exposure. Specifically, this study will test two general hypotheses. First, we hypothesize that pre-exposure to a relatively low concentration of NO2 will "sensitize" individuals to a subsequent O3 exposure and lead to greater changes in cardiopulmonary function compared to O3 exposure preceded by clean air exposure. Second, we hypothesize that pre-exposure to O3, at a concentration that has been previously associated with small changes in cardiopulmonary function, will prime individuals to have a greater response to NO2 compared to pre-exposure to clean air. The information obtained during the course of this study will enable the EPA to better evaluate the risks associated with sequential multi-pollutant exposure and potentially provide advice on activities to mitigate the effects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02133586
Study type Interventional
Source Environmental Protection Agency (EPA)
Contact
Status Completed
Phase N/A
Start date January 2014
Completion date January 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03441282 - Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression
Completed NCT02907255 - Vital Sign Monitoring With Continuous Pulse Oximetry and Wireless Clinician Notification After Surgery N/A
Completed NCT00544947 - Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids for Caesarean Section N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05391555 - Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age Phase 2/Phase 3
Completed NCT02481570 - Anesthetic Optimization in Scoliosis Surgery N/A
Completed NCT06083272 - VitalThings Guardian Contactless Monitoring
Not yet recruiting NCT06064409 - Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
Completed NCT00345384 - Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients Phase 1/Phase 2
Recruiting NCT04046068 - Multimodal Perioperative Pain Management: ComfortSafe Program
Recruiting NCT02819661 - Respiratory Depression in Women With BMI≥30 Underwent Spinal Anesthesia With Intrathecal Morphine in Elective C-section N/A
Active, not recruiting NCT04011163 - Vital Signs-Integrated Patient-Assisted Intravenous Opioid Analgesia for Post Surgical Pain Phase 2/Phase 3
Active, not recruiting NCT06374589 - Closed-Loop O2 Use During High Flow Oxygen Treatment Of Critical Care Adult Patients (CLOUDHFOT) N/A
Terminated NCT02760927 - Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes N/A
Completed NCT01869582 - Safer Births - Reducing Perinatal Mortality N/A
Completed NCT00875134 - Testing of the Apnea Prevention Device Phase 1/Phase 2
Not yet recruiting NCT06137638 - ENA-001 for Post Operative Respiratory Depression (PORD) Phase 2
Completed NCT01843933 - Detecting Post-Operative Respiratory Depression in Children N/A
Completed NCT00696137 - Long-term Extension Study of BEMA™ Fentanyl Phase 3
Completed NCT04017702 - Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring